威尔药业前三季度营收净利微增，暂无2026年重大事件披露

Core Viewpoint - The recent financial report of Weir Pharmaceutical (603351) indicates modest growth in revenue and net profit for the first three quarters of 2025, reflecting the company's stable performance amidst market conditions [1] Financial Performance - The company achieved a revenue of 1.018 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 1.79% [1] - The net profit attributable to shareholders reached 114 million yuan, showing a year-on-year growth of 1.03% [1] Corporate Activities - Weir Pharmaceutical held a shareholders' meeting on December 16, 2025, to review relevant proposals [1] - The schedule for the 2026 annual shareholders' meeting has not yet been announced [1] - No specific major events for 2026 have been disclosed in recent public information, indicating a need for investors to monitor upcoming regular reports and official announcements [1]